CyGen Alpha Systems names board and advisory leaders for isotope buildout

By AI, Created 10:26 PM UTC, May 27, 2026, /AGP/ – CyGen Alpha Systems has assembled board and advisory leadership as it advances a planned $65 million U.S. radiopharmaceutical manufacturing platform in Scottsdale, Arizona. The company says the move is meant to help ease isotope shortages and support growing demand for diagnostic imaging and targeted cancer therapies.

Why it matters: - CyGen Alpha Systems is building infrastructure meant to address U.S. medical isotope shortages that affect diagnostic imaging and targeted cancer treatment. - The company’s plan centers on a next-generation radiopharmaceutical manufacturing and CDMO platform designed to support theranostics and targeted alpha therapy. - The effort targets a gap between fast-moving radiopharma innovation and the physical infrastructure needed to produce and distribute isotopes at scale.

What happened: - CyGen Alpha Systems announced board and advisory leadership additions as it advances development of a planned radiopharmaceutical facility in Scottsdale, Arizona. - The company is planning a $65 million, 20,000-square-foot GMP radiopharmaceutical production facility. - The platform is intended to combine cyclotron-based isotope production, radiopharmacy operations, GMP manufacturing, and time-sensitive clinical distribution under one system.

The details: - CyGen’s facility is being designed to support programs involving astatine-211, lead-212, actinium-225, copper-64, and gallium-68. - The company expects to produce select isotopes directly. - CyGen also plans to support some therapeutic programs through qualified isotope supply partnerships and CDMO manufacturing relationships. - The company says the integrated model is meant to reduce supply chain fragmentation and improve development and commercialization timelines for radiopharmaceutical partners. - CyGen is advancing site acquisition, engineering, and development planning. - The company is targeting key project milestones for late 2026 through mid-2027. - CyGen is in active partnership discussions with isotope suppliers, equipment vendors, radiopharmaceutical developers, and clinical network participants. - The board includes John Murphy, Brandon Xiong, Dr. Andrew Lake Wooten, Ronn Riedel, and Kendall Friesen. - Murphy brings more than 30 years of development and construction leadership and has overseen more than $1.2 billion in large-scale projects. - Xiong provides technical leadership in cyclotron facilities and GMP radiopharmaceutical production. - Wooten brings experience in radiopharmaceutical development, isotope production, and GMP manufacturing. - Riedel has financial and regulatory experience supporting SEC-registered broker-dealers and investment firms. - Friesen brings more than 30 years of large-scale construction and permitting experience. - The advisory board includes Jason Morrell, Dr. Chad Regehr, Dr. Johannes Nagel, Dr. Tadashi Watabe, Dr. Peter Scott, Dr. Ming-Der Yu, and Dr. Kevin A. Maupin. - Advisory expertise spans GMP and external manufacturing, medical logistics, CMC, targeted alpha therapy, theranostics, clinical and isotope production, radiochemistry, imaging data, AI, and theranostics strategy. - The company said it welcomes engagement from investors, developers, isotope suppliers, and healthcare institutions. - A LinkedIn page is listed as the company’s social profile.

Between the lines: - The board and advisory slate signals that CyGen is trying to blend technical, regulatory, construction, and commercialization expertise in one platform. - The company’s structure suggests a bet that integrated infrastructure can be more useful to radiopharma partners than fragmented supply and manufacturing services. - The timing aligns with broader pressure on isotope supply as theranostics and targeted alpha therapy gain momentum.

What’s next: - CyGen is continuing site acquisition, engineering, and development work toward milestones expected between late 2026 and mid-2027. - The company is pursuing partnerships across the isotope supply chain and clinical distribution network. - Execution on facility buildout and partner alignment will determine how quickly the platform can move from planning to production.

The bottom line: - CyGen is positioning itself as an integrated U.S. isotope infrastructure player at a moment when radiopharmaceutical demand is rising faster than supply.